WHWK
Whitehawk Therapeutics Inc
Biotechnology
Market Cap$206M
5Y Perf.-77.8%
Build Your Comparison
Side-by-side financial analysisWHWK
NRXP
Try popular comparisons:
Stock Comparison
WHWK vs NRXP
Revenue, margins, valuation, and 5-year total return — side by side.
NRXP
NRx Pharmaceuticals, Inc.
Biotechnology
Market Cap$66M
5Y Perf.-96.3%
WHWK vs NRXP — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot |  WHWK |  NRXP |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $206M | $66M |
| Revenue (TTM) | $7M | $2M |
| Net Income (TTM) | $-21M | $-25M |
| Gross Margin | 89.3% | 37.1% |
| Operating Margin | -16.0% | -7.5% |
| Total Debt | $0.00 | $631K |
| Cash & Equiv. | $38M | $8M |
WHWK vs NRXP — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
WHWK
NRXP
| Stock | Jun 20 | Jun 26 | Return |
|---|---|---|---|
| Whitehawk Therapeut… (WHWK) | 100 | 22.2 | -77.8% |
| NRx Pharmaceuticals… (NRXP) | 100 | 3.7 | -96.3% |
Price return only. Dividends and distributions are not included.
Quick Verdict: WHWK vs NRXP
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: WHWK leads in 4 of 6 categories, making it the strongest pick for profitability and margin quality and capital preservation and lower volatility. NRx Pharmaceuticals, Inc. is the stronger pick specifically for growth and revenue expansion. As sector peers, any of these can serve as alternatives in the same allocation.
🥇WHWK emerged as the overall leader. Track its performance:
WHWK
Whitehawk Therapeutics Inc
The Income Pick
WHWK carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- Dividend streak 1 yrs, beta 1.68
- Rev growth -72.5%, EPS growth 86.0%, 3Y rev CAGR -22.3%
- -95.4% 10Y total return vs NRXP's -96.0%
Best for: income & stability and growth exposure
NRXP
NRx Pharmaceuticals, Inc.
The Growth Leader
NRXP is the clearest fit if your priority is growth.
- -7.6% revenue growth vs WHWK's -72.5%
Best for: growth
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth |  NRXP | -7.6% revenue growth vs WHWK's -72.5% |
| Quality / Margins |  WHWK | -288.3% margin vs NRXP's -10.7% |
| Stability / Safety | WHWK | Beta 1.68 vs NRXP's 2.05 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | WHWK | +103.9% vs NRXP's +11.6% |
| Efficiency (ROA) | WHWK | -11.2% ROA vs NRXP's -219.6% |
WHWK vs NRXP — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2025
FY 2025
WHWK vs NRXP — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLWHWKLAGGINGNRXP
NRXPNRx Pharmaceuticals, …
1leads
WHWKWhitehawk Therapeutic…
3leads
6 Total Categories
CATEGORYLEADERvs NRXPMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
NRXP3/5
Valuation MetricsMultiples, price ratios, and targets
WHWK2/2
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
WHWK3/4
Total Returns1Y, 3Y, 5Y total returns with dividends
WHWK4/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
NRXP leads this category, winning 3 of 5 comparable metrics.
Income & Cash Flow (Last 12 Months)
WHWK is the larger business by revenue, generating $7M annually — 3.1x NRXP's $2M. WHWK is the more profitable business, keeping -2.9% of every revenue dollar as net income compared to NRXP's -10.7%.
| Metric | WHWKWhitehawk Therape… | NRXPNRx Pharmaceutica… |
|---|---|---|
| RevenueTrailing 12 months | $7M | $2M |
| EBITDAEarnings before interest/tax | -$114M | -$31M |
| Net IncomeAfter-tax profit | -$21M | -$25M |
| Free Cash FlowCash after capex | -$98M | -$15M |
| Gross MarginGross profit ÷ Revenue | +89.3% | +37.1% |
| Operating MarginEBIT ÷ Revenue | -16.0% | -7.5% |
| Net MarginNet income ÷ Revenue | -2.9% | -10.7% |
| FCF MarginFCF ÷ Revenue | -13.7% | -6.5% |
| Rev. Growth (YoY)Latest quarter vs prior year | -100.0% | — |
| EPS Growth (YoY)Latest quarter vs prior year | +49.3% | +87.0% |
NRXP leads this category, winning 3 of 5 comparable metrics.
Valuation Metrics
WHWK leads this category, winning 2 of 2 comparable metrics.
Valuation Metrics
| Metric | WHWKWhitehawk Therape… | NRXPNRx Pharmaceutica… |
|---|---|---|
| Market CapShares × price | $206M | $66M |
| Enterprise ValueMkt cap + debt − cash | $168M | $59M |
| Trailing P/EPrice ÷ TTM EPS | -12.61x | -2.87x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | 28.79x | 54.19x |
| Price / BookPrice ÷ Book value/share | 1.89x | — |
| Price / FCFMarket cap ÷ FCF | — | — |
WHWK leads this category, winning 2 of 2 comparable metrics.
Profitability & Efficiency
WHWK leads this category, winning 3 of 4 comparable metrics.
Profitability & Efficiency
On the Piotroski fundamental quality scale (0–9), NRXP scores 6/9 vs WHWK's 3/9, reflecting solid financial health.
| Metric | WHWKWhitehawk Therape… | NRXPNRx Pharmaceutica… |
|---|---|---|
| ROE (TTM)Return on equity | -12.0% | — |
| ROA (TTM)Return on assets | -11.2% | -2.2% |
| ROICReturn on invested capital | -139.1% | — |
| ROCEReturn on capital employed | -120.7% | — |
| Piotroski ScoreFundamental quality 0–9 | 3 | 6 |
| Debt / EquityFinancial leverage | — | — |
| Net DebtTotal debt minus cash | -$38M | -$7M |
| Cash & Equiv.Liquid assets | $38M | $8M |
| Total DebtShort + long-term debt | $0 | $631,000 |
| Interest CoverageEBIT ÷ Interest expense | — | -34.34x |
WHWK leads this category, winning 3 of 4 comparable metrics.
Total Returns (Dividends Reinvested)
WHWK leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in WHWK five years ago would be worth $1,401 today (with dividends reinvested), compared to $213 for NRXP. Over the past 12 months, WHWK leads with a +103.9% total return vs NRXP's +11.6%. The 3-year compound annual growth rate (CAGR) favors NRXP at -10.5% vs WHWK's -19.1% — a key indicator of consistent wealth creation.
| Metric | WHWKWhitehawk Therape… | NRXPNRx Pharmaceutica… |
|---|---|---|
| YTD ReturnYear-to-date | +70.5% | +46.6% |
| 1-Year ReturnPast 12 months | +103.9% | +11.6% |
| 3-Year ReturnCumulative with dividends | -47.1% | -28.2% |
| 5-Year ReturnCumulative with dividends | -86.0% | -97.9% |
| 10-Year ReturnCumulative with dividends | -95.4% | -96.0% |
| CAGR (3Y)Annualised 3-year return | -19.1% | -10.5% |
WHWK leads this category, winning 4 of 6 comparable metrics.
Risk & Volatility
Evenly matched — WHWK and NRXP each lead in 1 of 2 comparable metrics.
Risk & Volatility
WHWK is the less volatile stock with a 1.68 beta — it tends to amplify market swings less than NRXP's 2.05 beta. A beta below 1.0 means the stock typically moves less than the S&P 500.
| Metric | WHWKWhitehawk Therape… | NRXPNRx Pharmaceutica… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.68x | 2.05x |
| 52-Week HighHighest price in past year | $5.50 | $5.05 |
| 52-Week LowLowest price in past year | $1.57 | $1.62 |
| % of 52W HighCurrent price vs 52-week peak | +75.7% | +76.0% |
| RSI (14)Momentum oscillator 0–100 | 45.5 | 55.1 |
| Avg Volume (50D)Average daily shares traded | 331K | 1.3M |
Evenly matched — WHWK and NRXP each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
| Metric | WHWKWhitehawk Therape… | NRXPNRx Pharmaceutica… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | — |
| Price TargetConsensus 12-month target | $7.00 | — |
| # AnalystsCovering analysts | — | — |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | 1 | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
WHWK leads in 3 of 6 categories (Valuation Metrics, Profitability & Efficiency). NRXP leads in 1 (Income & Cash Flow). 1 tied.
Best OverallWhitehawk Therapeutics Inc (WHWK)Leads 3 of 6 categories
Loading custom metrics...
WHWK vs NRXP: Frequently Asked Questions
7 questions · data-driven answers · updated daily
01Which is the better long-term investment — WHWK or NRXP?
Over the past 5 years, Whitehawk Therapeutics Inc (WHWK) delivered a total return of -86.
0%, compared to -97. 9% for NRx Pharmaceuticals, Inc. (NRXP). Over 10 years, the gap is even starker: WHWK returned -95. 4% versus NRXP's -96. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
02Which is safer — WHWK or NRXP?
By beta (market sensitivity over 5 years), Whitehawk Therapeutics Inc (WHWK) is the lower-risk stock at 1.
68β versus NRx Pharmaceuticals, Inc. 's 2. 05β — meaning NRXP is approximately 22% more volatile than WHWK relative to the S&P 500.
03Which is growing faster — WHWK or NRXP?
On earnings-per-share growth, the picture is similar: Whitehawk Therapeutics Inc grew EPS 86.
0% year-over-year, compared to 43. 9% for NRx Pharmaceuticals, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
04Which has better profit margins — WHWK or NRXP?
Whitehawk Therapeutics Inc (WHWK) is the more profitable company, earning -288.
3% net margin versus -23. 4% for NRx Pharmaceuticals, Inc. — meaning it keeps -288. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: NRXP leads at -1324. 4% versus -1601. 1% for WHWK. At the gross margin level — before operating expenses — WHWK leads at 89. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
05Which pays a better dividend — WHWK or NRXP?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
06Is WHWK or NRXP better for a retirement portfolio?
For long-horizon retirement investors, Whitehawk Therapeutics Inc (WHWK) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding.
NRx Pharmaceuticals, Inc. (NRXP) carries a higher beta of 2. 05 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (WHWK: -95. 4%, NRXP: -96. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
07What are the main differences between WHWK and NRXP?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.